415 related articles for article (PubMed ID: 28483946)
1. p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes.
Pappas K; Xu J; Zairis S; Resnick-Silverman L; Abate F; Steinbach N; Ozturk S; Saal LH; Su T; Cheung P; Schmidt H; Aaronson S; Hibshoosh H; Manfredi J; Rabadan R; Parsons R
Mol Cancer Res; 2017 Aug; 15(8):1051-1062. PubMed ID: 28483946
[No Abstract] [Full Text] [Related]
2. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways.
Feng Z; Hu W; de Stanchina E; Teresky AK; Jin S; Lowe S; Levine AJ
Cancer Res; 2007 Apr; 67(7):3043-53. PubMed ID: 17409411
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of NFkappaB-responsive gene expression by DeltaNp73alpha in p53 null cells.
Tanaka Y; Ota K; Kameoka M; Itaya A; Yoshihara K
Exp Cell Res; 2006 May; 312(8):1254-64. PubMed ID: 16430884
[TBL] [Abstract][Full Text] [Related]
4. Friend or Foe: MicroRNAs in the p53 network.
Luo Z; Cui R; Tili E; Croce C
Cancer Lett; 2018 Apr; 419():96-102. PubMed ID: 29330109
[TBL] [Abstract][Full Text] [Related]
5. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents.
Do MT; Kim HG; Choi JH; Jeong HG
Free Radic Biol Med; 2014 Sep; 74():21-34. PubMed ID: 24970682
[TBL] [Abstract][Full Text] [Related]
6. BTG2 is a tumor suppressor gene upregulated by p53 and PTEN in human bladder carcinoma cells.
Tsui KH; Chiang KC; Lin YH; Chang KS; Feng TH; Juang HH
Cancer Med; 2018 Jan; 7(1):184-195. PubMed ID: 29239139
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B Virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells.
Chung TW; Lee YC; Ko JH; Kim CH
Cancer Res; 2003 Jul; 63(13):3453-8. PubMed ID: 12839924
[TBL] [Abstract][Full Text] [Related]
8. PTEN: a default gate-keeping tumor suppressor with a versatile tail.
Wang X; Jiang X
Cell Res; 2008 Aug; 18(8):807-16. PubMed ID: 18626510
[TBL] [Abstract][Full Text] [Related]
9. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein.
Paramio JM; Navarro M; Segrelles C; Gómez-Casero E; Jorcano JL
Oncogene; 1999 Dec; 18(52):7462-8. PubMed ID: 10602505
[TBL] [Abstract][Full Text] [Related]
10. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
11. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
12. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN.
Regina S; Valentin JB; Lachot S; Lemarié E; Rollin J; Gruel Y
Clin Chem; 2009 Oct; 55(10):1834-42. PubMed ID: 19661141
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.
Wu Z; He B; He J; Mao X
Prostate; 2013 May; 73(6):596-604. PubMed ID: 23060044
[TBL] [Abstract][Full Text] [Related]
14. Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells.
Pires MM; Hopkins BD; Saal LH; Parsons RE
Cancer Biol Ther; 2013 Mar; 14(3):246-53. PubMed ID: 23291982
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers.
Oliveira AM; Ross JS; Fletcher JA
Am J Clin Pathol; 2005 Dec; 124 Suppl():S16-28. PubMed ID: 16468415
[TBL] [Abstract][Full Text] [Related]
16. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
17. The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review).
Nakanishi A; Kitagishi Y; Ogura Y; Matsuda S
Int J Oncol; 2014 Jun; 44(6):1813-9. PubMed ID: 24718924
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-17 promotes normal ovarian cancer cells to cancer stem cells development via suppression of the LKB1-p53-p21/WAF1 pathway.
Liu T; Qin W; Hou L; Huang Y
Tumour Biol; 2015 Mar; 36(3):1881-93. PubMed ID: 25510663
[TBL] [Abstract][Full Text] [Related]
19. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG
Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308
[TBL] [Abstract][Full Text] [Related]
20. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells.
Zhou M; Gu L; Findley HW; Jiang R; Woods WG
Cancer Res; 2003 Oct; 63(19):6357-62. PubMed ID: 14559824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
